Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v2-FR | Version v2-FR | |
---|---|---|
Language | French | French |
Date Updated | 2024-10-07 | 2024-10-07 |
Drug Identification Number | 02247725 | 02247725 |
Brand name | FUZEON | FUZEON |
Common or Proper name | ENFUVIRTIDE | ENFUVIRTIDE |
Company Name | HOFFMANN-LA ROCHE LIMITED | HOFFMANN-LA ROCHE LIMITED |
Ingredients | ENFUVIRTIDE | ENFUVIRTIDE |
Strength(s) | 108MG | 108MG |
Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
Additional packaging sizes | 60 X 3ML VIAL | 60 X 3ML VIAL |
ATC code | J05AX | J05AX |
ATC description | DIRECT ACTING ANTIVIRALS | DIRECT ACTING ANTIVIRALS |
Reason for discontinuation | Manufacturing issues | Manufacturing issues |
Anticipated discontinuation date | 2025-03-31 | 2025-03-31 |
Actual discontinuation date | ||
Remaining supply date | 2025-03-31 | 2025-03-31 |
Discontinuation status | To be discontinued | To be discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | ||
Health Canada comments |